



Training dogs to differentiate *Pseudomonas aeruginosa* from other cystic fibrosis bacterial pathogens: not to be sniffed at?

To the Editor:

The major cause of lung damage in cystic fibrosis (CF) is infection with bacterial pathogens, the most prevalent of which is *Pseudomonas aeruginosa*, chronically infecting ~60% patients by adolescence/adulthood (www.cysticfibrosis.org.uk/news/registry-report-2017). *P. aeruginosa* may be successfully eradicated, but frequently recurs and establishes biofilms resistant to antibiotics/host defences [1]. Chronic *P. aeruginosa* is closely linked with pulmonary exacerbation frequency, faster lung function decline and earlier mortality [2]. The huge antibiotic burden imposed upon patients and the resulting bacterial resistance, allergies and toxicities compound the detrimental impact of the infection itself. Chronic *P. aeruginosa* should be avoided if at all possible; early detection and rapid treatment may be crucial in achieving this.

Currently, bacterial infections are detected by culture of airway samples at clinic attendance (2–3 monthly). In the absence of new symptoms, long periods could therefore ensue between cultures. Furthermore, while sputum is most commonly obtained from adults with established bronchiectasis, children and those with milder lung disease rely on cough/throat swabs. These lack specificity and, in some studies, sensitivity, so infections can be missed [3]. More reliable techniques such as sputum induction are time-consuming and expensive, while the gold standard, bronchoalveolar lavage, is invasive so neither technique can be undertaken regularly. Serology has been used with some success, but is not generally performed frequently as accuracy remains somewhat controversial and it requires invasive blood tests [4]. With the improving health of current CF cohorts, obtaining reliable samples from non-sputum producers will become an increasing challenge.

Several teams, including our own, have explored the utility of breath sampling for *P. aeruginosa* detection. CARROLL *et al.* [5] tested the head-space of culture plates in sealed bags with selected ion flow tube mass spectrometry demonstrating higher levels of hydrogen cyanide (HCN) with *P. aeruginosa* cultures. The group later reported that the presence of HCN in CF breath lacked the sensitivity to detect early *P. aeruginosa* infection [6]. We used a similar technique to test a combination of volatile organic compounds in breath, also finding insufficient ability to distinguish infected from non-infected on an individual basis [7]. Within the Strategic Research Centre for *Pseudomonas* in CF, we continue to explore several of these technologies; however, in parallel, we have explored training the canine nose as a detection system.

Sniffer dogs are familiar in contexts such as airport security, and reports of their use in medical fields are established (diabetes [8]) and emerging (recognising seizure-related auras [9] and detection of cancers [10]). Given the natural odour of *P. aeruginosa*, we hypothesised that dogs can be trained to detect this organism. One small study, available only in abstract form [11], would suggest this is a fruitful endeavour. As a first step we have assessed the ability of dogs to identify *P. aeruginosa* from other CF bacteria in culture supernatants.

 @ERSpublications

Detection dogs can be trained to distinguish the major cystic fibrosis pathogen, *P. aeruginosa*, from a range of organisms. High sensitivity/specificity support the harnessing of this skill to detection in clinical airway samples. <http://bit.ly/31GHI0Y>

Cite this article as: Davies JC, Alton E, Simbo A, *et al.* Training dogs to differentiate *Pseudomonas aeruginosa* from other cystic fibrosis bacterial pathogens: not to be sniffed at? *Eur Respir J* 2019; 54: 1900970 [<https://doi.org/10.1183/13993003.00970-2019>].





FIGURE 1 a) During training and subsequent testing, samples are presented to dogs in a specially designed rig or row of metal arms, which allows them to sniff the headspace above the sample, move on if they consider it “negative” and indicate at a “positive”. A dog could indicate by sitting or standing still; the method of response was consistent within an individual. A negative sample was usually abandoned in 1–2 s, the dog moving onto the next sample. When the dog gave a positive indication, the sniffing of that sequence was halted, and they were rewarded if appropriate. An incorrect indication resulted in no reward. Any sample which had not been encountered in that run (*i.e.* was after a correctly identified positive), was placed into a subsequent run so that each dog encountered every sample and control. b) Exact 95% confidence intervals for the sensitivity and specificity of each dog (named) in each trial. Study 1: *Pseudomonas aeruginosa* versus controls on which the dogs had been trained; Study 2: *P. aeruginosa* versus new controls (different organisms which the dogs had not previously encountered); Study 3: *P. aeruginosa* versus controls at 1:1000 (blue) and 1:10000 (red) dilutions; Study 4: *P. aeruginosa* mixed in culture with other organisms.

CF bacterial strains were obtained from the microbiology laboratory of the Royal Brompton Hospital and stored on beads at -80°C prior to culture on agar plates. Each isolate was from an individual patient, but as isolates have not been typed or sequenced, some strains may have been shared. Following overnight culture at 37°C in broth ($\sim 10^9$ CFU $\cdot\text{mL}^{-1}$), they were centrifuged at 3900 xg (15 min) and the supernatant removed and filtered through 0.2 μm disc filter.

Dogs were trained and tested on customised sample presentation stands within which supernatants were presented just below head height under a grill (figure 1a). During training, correct identification of *P. aeruginosa* samples was rewarded by an auditory click and food reward. Once trained, dogs were presented with *P. aeruginosa*-positive samples, other bacterial controls or sterile broth in a random, computer-generated sequence. A positive indication (dog stopped or sat down) was rewarded if correct. In the double-blind testing, the indication was entered into an electronic spreadsheet, which immediately revealed the correct identification of the sample, allowing the dog to be rewarded if appropriate. Four blinded studies were undertaken: 1) *P. aeruginosa* versus other bacteria familiar to the dogs; 2) *P. aeruginosa* versus previously unencountered bacteria; 3) dilution testing (1:1000 and 1:10 000); and 4) mixed, multi-organism cultures. Exact 95% confidence intervals were calculated for the sensitivity and specificity of each dog in each study, based on their first encounter with each sample. Analyses were undertaken using SAS V9.4 (SAS Institute Inc., Cary, NC, USA).

In the first study, *P. aeruginosa* was tested alongside *Staphylococcus aureus*, *Moraxella catarrhalis* and sterile broth (598 samples per dog; three dogs). Mean sensitivity (correct signalling at a *P. aeruginosa* sample) was 94.2% with a specificity of 98.5% (figure 1b). In the second study, we tested the dogs' ability to identify *P. aeruginosa* when the controls were bacteria to which they had not been previously exposed: *Achromobacter xylosoxidans*, *Burkholderia cepacia* complex, *Stenotrophomonas maltophilia* and *Serratia marcescens* (166 samples per dog). Two of the three dogs maintained sensitivity $>90\%$, but in the third it was lower at 62.5%. The dogs were most likely to give a false positive indication at *B. cepacia* complex (specificity 76.9%). In the third study, two dogs were tested on diluted broths (114 samples per dog). At dilutions of 1:1000 no substantial impact on sensitivity (93.8%) or specificity (94.9%) was seen, but at 1:10 000, sensitivity was lower (56.3%) although specificity was maintained (89.1%). In the fourth and final study, when all four dogs were tested for their ability to detect *P. aeruginosa* in a mixed culture with either one or two other organisms (*Haemophilus influenzae*, *S. aureus* and *M. catarrhalis*, 104 samples per dog), they still correctly identified *P. aeruginosa* with a sensitivity of 86.5% and a specificity of 84.1%.

In this series of pilot studies, we have confirmed that, following training, dogs can detect the odour of *P. aeruginosa* in broth supernatants with high levels of sensitivity, distinguishing them from other bacteria commonly encountered in the CF lung. This ability was generally maintained when the dogs encountered other organisms for the first time, or when *P. aeruginosa* was present in mixed cultures. Sensitivity declined at dilutions of 1:10 000, equating to $\sim 10^5$ CFU $\cdot\text{mL}^{-1}$.

The mode of growth of *P. aeruginosa* in broth is significantly different from that in the CF airway and the volatile signals generated will also probably differ. While it is unlikely training on broth will be sufficient for detection on clinical samples, these studies provided useful proof-of-principle for the concept. Had we been unable to train dogs on this substrate further development into the clinic would probably have been futile. We note the reduced sensitivity of *P. aeruginosa* detection once broth supernatant was diluted. Although the bacterial burden in the chronically-infected CF airway can be as high as 10^9 CFU $\cdot\text{mL}^{-1}$, the numbers of organisms in early infection will be much lower. This may pose a limitation to this technique, which we will test at the next stage.

We are often questioned about the clinical utility of this method should it prove successful. While the presence of dogs in our CF clinics might be viewed positively by some of our patients, particularly the children, this is clearly not the way forward. Rather, we aim to develop a non-sputum, non-culture-based test that can be performed by people with CF on a frequent basis. This could involve breath, cough/huff tissues, exhaled breath condensate or even urine. Samples could be collected at home by people with CF and sent to Medical Detection Dogs for screening, a positive indication would then lead to clinical assessment for conventional testing. Once we have optimised the next stage of training, we will perform a direct head-to-head comparison of this method with available "electronic noses" or mass spectrometry-based techniques. Compared with new technologies, dogs may ultimately prove more sensitive or more affordable for screening lower airway infection in CF.

Jane C. Davies^{1,2}, Eric Alton^{1,2}, Ameze Simbo¹, Ronan Murphy¹, Ishani Seth¹, Kate Williams³, Mark Somerville³, Libby Jolly³, Steve Morant³ and Claire Guest³

¹National Heart and Lung Institute, Imperial College, London, UK. ²Royal Brompton and Harefield NHS Foundation Trust, London. ³Medical Detection Dogs, Milton Keynes, UK.

Correspondence: Jane C. Davies, National Heart and Lung Institute, Imperial College London, 1B Manresa Rd, London SW3 6LR, UK. E-mail: j.c.davies@imperial.ac.uk

Received: 14 May 2019 | Accepted after revision: 02 July 2019

Conflict of interest: J.C. Davies reports other from Aligpharma AS (advisory board and clinical trial lead), other from Bayer AG (UK lead investigator and advisory board), other from Boehringer Ingelheim Pharma GmbH&Co. KG (advisory board), other from Galapagos NV (advisory board, clinical trial leadership), other from ImevaX GmbH (advisory and trial design assistance), other from Nivalis Therapeutics, Inc. (advisory board), other from ProQR Therapeutics III B.V. (advisory board and advice on trial design), other from Proteostasis Therapeutics, Inc. (advisory and clinical trial leadership), other from Raptor Pharmaceuticals, Inc. (advisory board), other from Vertex Pharmaceuticals (Europe) Limited (advisory board and National Co-ord/Global Co-I), other from Enterprise (advisory board), other from Novartis (advisory board), other from Pulmocide (advisory board), other from Flatley (advisory board), other from Nivalis Therapeutics Inc. (advisory board), grants from CF Trust, other from Teva (educational activities), outside the submitted work. E. Alton has nothing to disclose. A. Simbo has nothing to disclose. R. Murphy has nothing to disclose. I. Seth has nothing to disclose. K. Williams has nothing to disclose. M. Somerville has nothing to disclose. L. Jolly has nothing to disclose. S. Morant has nothing to disclose. C. Guest has nothing to disclose.

References

- 1 Heltshe SL, Khan U, Beckett V, *et al.* Longitudinal development of initial, chronic and mucoid *Pseudomonas aeruginosa* infection in young children with cystic fibrosis. *J Cyst Fibros* 2018; 17: 341–347.
- 2 Maurice NM, Bedi B, Sadikot RT. *Pseudomonas aeruginosa* biofilms: host response and clinical implications in lung infections. *Am J Respir Cell Mol Biol* 2018; 58: 428–439.
- 3 Ahmed B, Bush A, Davies JC. How to use: bacterial cultures in diagnosing lower respiratory tract infections in cystic fibrosis. *Arch Dis Child Educ Pract Ed* 2014; 99: 181–187.
- 4 Mauch RM, Levy CE. Serum antibodies to *Pseudomonas aeruginosa* in cystic fibrosis as a diagnostic tool: a systematic review. *J Cyst Fibros* 2014; 13: 499–507.
- 5 Carroll W, Lenney W, Wang T, *et al.* Detection of volatile compounds emitted by *Pseudomonas aeruginosa* using selected ion flow tube mass spectrometry. *Pediatr Pulmonol* 2005; 39: 452–456.
- 6 Gilchrist FJ, Belcher J, Jones AM, *et al.* Exhaled breath hydrogen cyanide as a marker of early *Pseudomonas aeruginosa* infection in children with cystic fibrosis. *ERJ Open Res* 2015; 1: 00044-2015.
- 7 Pabary R, Huang J, Kumar S, *et al.* Does mass spectrometric breath analysis detect *Pseudomonas aeruginosa* in cystic fibrosis? *Eur Respir J* 2016; 47: 994–997.
- 8 Rooney NJ, Guest CM, Swanson LCM, *et al.* How effective are trained dogs at alerting their owners to changes in blood glycaemic levels? Variations in performance of glycaemia alert dogs. *PLoS One* 2019; 14: e0210092.
- 9 Martos Martinez-Caja A, De Herdt V, Boon P, *et al.* Seizure-alerting behavior in dogs owned by people experiencing seizures. *Epilepsy Behav* 2019; 94: 104–111.
- 10 Willis CM, Britton LE, Harris R, *et al.* Volatile organic compounds as biomarkers of bladder cancer: Sensitivity and specificity using trained sniffer dogs. *Cancer Biomark* 2010-2011; 8: 145–153.
- 11 Johnston NV, Rao J, Elborn JS, *et al.* Canine detection of *Pseudomonas aeruginosa* (PA) volatile organic compounds (VOC's). *J Cystic Fibr* 2012; 11: Suppl. 1, S87.

Copyright ©ERS 2019